


CDK8-IN-13

Chemical Properties

CAS No. :	918523-75-8
Formula:	C ₁₄ H ₁₁ N ₃ O
Molecular Weight:	237.26
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	CDK8-IN-13 is a CDK8 inhibitor (IC ₅₀ : 51.9 nM) with potent, selective and oral activity. CDK8-IN-13 induces apoptosis and reduces the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 exhibits anti-tumour activity.
Targets(IC ₅₀)	Apoptosis,CDK
In vitro	CDK8-IN-13 (compound 43 ; 1, 2.5, 5, 10 μM ; 12 h) decreased p-STAT1 S727 and p-STAT5 S726 expression in HCT-116 cells in a dose-dependent manner.[1] CDK8-IN-13 (0, 1, 5, 10 μM ; 48 h) induced apoptosis in a dose-dependent manner.[1]
In vivo	CDK8-IN-13 (40, 80 mg/kg ; orally ; for 15 days) inhibits tumor growth in a dose-dependent manner in mice.[1]

Solubility Information

Solubility	DMSO: 112.5 mg/mL (474.16 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	4.2148 mL	21.0739 mL	42.1479 mL
5 mM	0.843 mL	4.2148 mL	8.4296 mL
10 mM	0.4215 mL	2.1074 mL	4.2148 mL
50 mM	0.0843 mL	0.4215 mL	0.843 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Zhang XX, et al. Discovery of a novel oral type I CDK8 inhibitor against acute myeloid leukemia. Eur J Med Chem. 2023 ; 251:115214.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481